Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Conditions

Paget's Disease of the Vulva

What is the purpose of this trial?

This is a phase II open-label study of the activity and safety of trastuzumab in patients with vulvar Paget's disease with overexpression of HER2 on biopsy.



Participation Guidelines

Age:
18 Years - N/A
Gender:
Female

Click here for detailed information about who can participate in this trial.


Sponsor:
Genentech
Yale University
Dates:
August 2011
Last Updated:
June 12, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01427244